Safe Use of Microbial Biocontrol Agents : A Canadian Industry Perspective by Dupont, Stéphane
Érudit est un consortium interuniversitaire sans but lucratif composé de l'Université de Montréal, l'Université Laval et l'Université du Québec à
Montréal. Il a pour mission la promotion et la valorisation de la recherche. Érudit offre des services d'édition numérique de documents
scientifiques depuis 1998.
Pour communiquer avec les responsables d'Érudit : info@erudit.org 
Article
 
"Safe Use of Microbial Biocontrol Agents : A Canadian Industry Perspective"
 
Stéphane Dupont
Phytoprotection, vol. 79, n° 4, 1998, p. 27-30.
 
 
 
Pour citer cet article, utiliser l'information suivante :
 
URI: http://id.erudit.org/iderudit/706152ar
DOI: 10.7202/706152ar
Note : les règles d'écriture des références bibliographiques peuvent varier selon les différents domaines du savoir.
Ce document est protégé par la loi sur le droit d'auteur. L'utilisation des services d'Érudit (y compris la reproduction) est assujettie à sa politique
d'utilisation que vous pouvez consulter à l'URI https://apropos.erudit.org/fr/usagers/politique-dutilisation/
Document téléchargé le 13 février 2017 04:52
Research Challenges and Needs for Safe Use of 
Microbial Organisms - an Industrial Perspective 
Safe Use of Microbial Biocontrol Agents: 
A Canadian Industry Perspective 
Stéphane Dupont 
Executive Director, BioProducts Centre Inc. Saskatoon, Canada 
THE CANADIAN 
ENVIRONMENT 
Canada's size, climate and natural re-
sources are well known around the 
world. With a land surface area of 
9.2 M km2 and a population of 30.3 M 
people, Canadians are used to wide 
open spaces. The forest land accounts 
for 4.2 M km2, a sizeable 10% of the 
world's forests. Canada is the world's 
largest exporter of timber products, 
commercially exploiting 28% of its for-
ests. Annually, 128,000 km2 of forests 
are affected by defoliating insects and 
66,000 km2 are lost to fires. 
Farmland represents 680,000 km2, 
which combines with the small popula-
tion to make Canada a major exporter 
of agricultural commodities. Over half 
of our exports go to the U.S., while the 
rest goes around the world, with Japan, 
the E.U. and China as the next major 
clients. Table 1 shows an overview of 
the Canadian agricultural commodities 
usually targeted for biocontrol. 
The growing season is short and farm-
ing often involves large areas managed 
with minimum tillage and inputs, re-
sulting in relatively lowyields compared 
to many other OECD countries. This is 
especially true of wheat farming in the 
prairies and has certain implications for 
biological control since the cost of pro-
duction of biologicals usually puts thèse 
products well above what the farmer 
can afford. Timber, as a crop, is akin to 
wheat, with very low margins and in-
puts. Oilseed production is represented 
mainly by canola in the prairie provinc-
es. Canola oil is a premium product and 
the better margins make biocontrol a 
potentially more viable option. Fruits 
and vegetables tend to be more propi-
tious crops for commercial biocontrol 
products, as in most other countries. 
The Canadian livestock industry is also 
very interested in using biocontrol prod-
ucts against both insect pests of cattle 
and noxious weeds of pasture and 
rangeland. 
Canada's rigorous winter has a ma-
jor impact on both pests and the bio-
control options available to manage 
them. We tend to hâve fewer pests, 
especially diseases and, to a certain 
extent, insects. With fewer pest génér-
ations peryear, résistance appears more 
slowly. Winter can also play a signifi-
Table 1: Market Value of Canadian Agricultural Production (Cdn $ B) 
Commodities British Prairie Ontario & Maritime Canada 
Columbia Provinces Québec Provinces 
Grains 0.02 5.14 0.83 0.02 6.01 
Oilseeds 0.01 2.24 0.89 <0.01 3.14 
Fruits & Veg. 0.30 0.08 1.05 0.09 1.52 
Other Crops 0.42 1.18 1.63 0.32 3.55 
Red méats 0.29 4.60 2.91 0.18 7.98 
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cant rôle in preventing or delaying the 
long-term establishment of a new bio-
control agent. This may be désirable for 
an inundative agent used outside of its 
natural range or undesirable for a clas-
sical agent. 
INDUSTRY PERSPECTIVE 
Canada has traditionally been at the 
forefront of biocontrol research and 
there is a large biocontrol scientific 
community in Universities and govern-
ment institutions (mainly the research 
centres of Agriculture and Agri-Food 
Canada and the Canadian Forest Ser-
vice). Unfortunately, this has not result-
ed in the development of a large private 
sector. This sector is made up of two 
distinct types of companies. On the one 
hand, there are the large crop protec-
tion multinationals, whose interest in 
biological control is increasingly direct-
ed at pest résistant transgenic crops, 
and on the other, about 15 small to very 
small companies involved in the devel-
opment and manufacture of other bio-
control products (mainly microbiais and 
a few insect agents). A few other com-
panies distribute products manufac-
tured abroad in addition to having lim-
ited R&D activities. The case of Bt is a 
telling example of the gulf between 
public research and commercialisation. 
A large amount of R&D work has been 
carried out in Canada on ail aspects of 
this type of product, from fundamental 
biochemistry to forestry and agriculture 
applications, but there is no Canadian 
manufacturer and Canada must import 
the products from the U.S. 
Ail the Canadian biocontrol company 
contacts identified were sent a list of 
questions. Thèse aimed to détermine 
the main issues regarding the commer-
cial development of safe new biocon-
trol products and the companies' rec-
ommendations for research priorities. 
About two-thirds of those contacted 
provided feedback. Most of the respon-
dents felt that the Canadian registration 
requirements are quite stringent and 
comprehensive in addressing the po-
tential risks associated with usage of 
new, non-modified, microbial biocon-
trol products. A minority felt that the 
authorities are focusing too much on 
selected non-target species, to the dét-
riment of a more ecological approach 
assessing long-term impact on the biodi-
versity of the various eco-regions. It 
was suggested that microbial biodiver-
sity banks représentative of the many 
Canadian agro-eco-regions could be es-
tablished as a safeguard against un-
foreseen effects. However, the above 
suggestions would represent a major, if 
not insurmountable, logistical, financial 
and scientific challenge. 
Most of the respondents from the 
small companies expressed some de-
gree of unease regarding the use of 
transgenic microorganisms. This was 
often based on the belief that only a 
small fraction of microorganisms are 
known (an estimated 1%) and that our 
knowledge of microbial ecology, and 
especially, latéral gène transfer mech-
anisms among microbes, is thought to 
be very limited. Another concern is that 
transgenic organisms relying on a sin-
gle mechanism of action are more like-
ly to induce résistance in the target 
pests. Similarly, non-modified organ-
isms also relying on simple mechanisms 
are considered more "resistance-prone" 
than those deploying more complex 
mechanisms. Some expressed the opin-
ion that, by placing a greater emphasis 
on the design of appropriate screening 
procédures, natural microorganisms 
with the desired profiles can be found 
without having to resort to genetic 
engineering. 
In addition to the safety issues dis-
cussed above, most respondents com-
mentée! on other aspects of the Canadi-
an regulatory framework for biocontrol 
agents. This framework is structured as 
follows: microbial pest control agents 
(as well as synthetic and natural chem-
ical pesticides) are regulated by the Pest 
Management Regulatory Agency 
(Health Canada). Growth promoting 
inoculants, macro-invertebrates and 
transgenic crops are reviewed by the 
Canadian Food Inspection Agency 
(now independent but formerly within 
Agriculture and Agri-Food Canada). AN 
biocontrol agents produced or under 
development by the respondents fall 
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within the mandate of one of thèse two 
agencies. A third organisation, the Ca-
nadian Environmental Protection Agen-
cy, deals with ail other new biological 
products. Unless specified otherwise, 
(Canadian regulatory) "agencies" will 
be used hère in référence to the PMRA 
and the CFIA. 
Several respondents indicated that 
minimal risks are sometimes given 
much more weight than they deserve 
by reviewers while the benefits of intro-
ducing a safe and effective alternative 
to chemical pesticides are not valued 
highly enough. In this context,the issue 
of commercial development of prod-
ucts containing ubiquitous, normally 
harmless, microorganisms, which may 
become opportunistic pathogens in in-
dividuals with severely depressed im-
munity, is of concern. Since thèse prod-
ucts normally pass stringent safety tests, 
it was felt that potential health prob-
lems, which might occur in very un-
common situations, should not lead to 
the rejection of the application when 
they could be safely addressed with 
appropriate delivery Systems, use pat-
terns and precautionary statements. 
Most companies wish for improve-
ments in the time taken to clarify final 
data requirements and complète the 
submission reviews. Any speeding up 
of registration and streamlining of as-
sociated bureaucratie processes will 
reduce development costs, which is 
especially important for the small com-
panies. The fact that PMRA reviewers 
often appear more accustomed to deal-
ing with chemical pesticides than mi-
crobiais was also mentioned. New 
chemical pesticides usually hâve no 
health or environmental history where-
as considérable information is often 
available on microbial agents. Solid 
expertise in the ecology, biology, mode 
of action and benefits of microbial con-
trol agents is needed on the part of both 
registrants and reviewers to evaluate 
ail existing relevant information. This 
information should be taken into ac-
count when determining the registra-
tion requirements. Some companies 
hâve also expressed the wish that agen-
cies show more flexibility in consider-
ing their prior registration data when 
reviewing new submissions for similar 
products (e.g. same organism, différent 
formulation; or very similar agent for 
the same target application). Finally, 
when only limited information exists in 
the literature about a new agent, it is 
often indicative of a species with no 
history of pathogenicity. The lack of 
prior information should, therefore, not 
raise undue concerns with reviewers. 
Both agencies hâve established new 
registration guidelines overthe pastfew 
years, which are generally highly re-
garded. The registrant-agency consul-
tations in advance of the final submis-
sions are greatly appreciated by ail 
respondents but especially by the small 
companies who lack the resources to 
employ full-time registration personnel 
and for whom an early définition of the 
studies required (i.e. registration R&D 
costs) is extremely useful. 
Commercial development issues are 
at the forefront of industry concerns in 
Canada, as they are elsewhere. There 
are many go/no-go décision points in 
the commercial development of a bio-
control product. Efficacy and cost of the 
final products are the main factors 
governing their adoption by the users. 
Biologicals are often associated with 
high production costs; low, slow or 
inconsistent efficacy; and short shelf 
lives. Thèse concerns are most com-
monly cited by the respondents as 
obstacles to the successful commercial-
isation of new biological products. 
Companies, large and small, usually see 
addressing thèse issues as their respon-
sibility and best done on a product by 
product basis. Other issues include the 
investment and expertise needed to 
develop high performance Quality As-
surance assays and formulations, and 
effectively market the new products. 
Various aspects of the commercial de-
velopment issues mentioned above 
greatly benefitfrom collaborations with 
experts in the public sector. The main-
tenance and expansion of the matching 
public funding options for thèse collab-
orations is strongly encouraged. Final-
ly, Canada currently lacks scale-up fa-
cilities for fermentation, downstream 
processing and formulation. Develop-
ing thèse is a major challenge and would 
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strongly benefit from a concerted ap-
proach between the government(s) and 
the private sector. 
Several respondents also indicated 
that applied public research in inunda-
tive biocontrol (i.e. work aiming for the 
eventual widespread use of a product) 
should, like industry, take économie 
viability into considération as early as 
possible. Even for products developed 
on a "public good" basis (high user or 
public need but no interest or possibil-
ity for the private sector to invest heavi-
ly in the commercial development), the 
économie feasibility must still be real-
istically evaluated. The total cost to 
complète the proof of concept work on 
économie, regulatory and technical 
feasibility is usually about Cdn $ 0.4 to 
0.8 M. A further $ 2 to 5 M is then 
needed to complète the efficacy, regis-
tration and process R&D work, without 
including the cost of the production 
facility or marketing the product. This 
emphasises the need for effective col-
laborations between the public and 
private research sectors, and the im-
portance of flexible funding options for 
the inherently riskier commercial proof 
of concept phase of a project. 
MAIN RECOMMENDATIONS 
AND OUTLOOK 
Various suggestions deemed helpful by 
the Canadian industrial biocontrol sec-
tor hâve been made so far. However, 
the recommendations respondents 
were most eager to put forward as pri-
ority areas for a concerted effort of the 
various biocontrol sectors were: a) sup-
port for basic research in microbiology 
and b) information of the public and 
potential users. Advances in the fields 
of microbial/soil ecology, biochemistry, 
physiology, molecular microbiology, 
etc. would hâve a major long-term 
impact on most aspects of safety and 
commercia l development of new 
agents. In addition there is an increas-
ing réalisation that, for any new prod-
ucts to be used in the environment and/ 
or the food chain, using the best pos-
sible science to ensure the best possi-
ble risk/benefit ratio is no longer 
enough. Effectively communicating ac-
curate information about the products, 
their risks and benefits to the public is 
equally indispensable. Past and current 
expériences with public debate and 
perception of chemical pesticides and 
transgenic crops in Canada and abroad 
hâve demonstrated the need for effec-
tive communications. The confidence 
of the Canadian public in the regulatory 
authorities to ensure safety of new prod-
ucts with respect to the food chain and 
the environment remains generally high 
but cannot be taken for granted. 
Over the past few years, Canada has 
developed a mechanism to fund high 
profile networks in areas where coordi-
nation of the research among scientists 
and with the private sector will resuit in 
maximum benefits for Canadian Soci-
ety. This is the Networks of Centres of 
Excellence Program and a funding ap-
plication for a Biocontrol Network was 
submitted in May 1998. Producing the 
complex application document was the 
first time that représentatives of ail the 
différent fields of biocontrol research in 
Canada worked together for a common 
goal. Research on products with a high 
potential for commercial success, in 
collaboration with the private sector, is 
a major priority of this network. How-
ever, other aspects discussed above are 
also featured prominently, such as ba-
sic science and improved communica-
tions among ail biocontrol stakehold-
ers and with the gênerai public. The 
network will hâve a strong IPM compo-
nent to ensure optimum long-term ef-
ficacy of the new products when used 
with each other and with existing pest 
management products and methods. 
The main targets are insect pests, dis-
eases, and weeds in forestry, canola, 
fruits and vegetables, as well as insects 
and weeds of concern to the livestock 
industry. The Biocontrol Network will 
be ideally placed to coordinate research 
and other activities in the priority areas 
most relevant for Canada. 
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